InflaRx (IFRX) has released an update.
InflaRx has showcased promising data at the ATS 2024 International Conference, revealing that their drug vilobelimab, when combined with standard immunomodulators, significantly reduced mortality in severely ill COVID-19 patients. This post-hoc analysis of the PANAMO Phase III trial demonstrated an 84.6% relative reduction in 28-day mortality when vilobelimab was used alongside tocilizumab or baricitinib, compared to placebo. These findings support the drug’s emergency use authorization granted by the FDA and highlight its potential in treating critical COVID-19 cases without raising safety concerns.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.
